| __timestamp | Amphastar Pharmaceuticals, Inc. | Catalyst Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 4473654 |
| Thursday, January 1, 2015 | 46974000 | 8597010 |
| Friday, January 1, 2016 | 47298000 | 7910260 |
| Sunday, January 1, 2017 | 50918000 | 7304399 |
| Monday, January 1, 2018 | 58044000 | 15875961 |
| Tuesday, January 1, 2019 | 63109000 | 36881187 |
| Wednesday, January 1, 2020 | 65157000 | 44233754 |
| Friday, January 1, 2021 | 68920000 | 49628000 |
| Saturday, January 1, 2022 | 66592000 | 58183000 |
| Sunday, January 1, 2023 | 80393000 | 133710000 |
Unlocking the unknown
In the competitive landscape of pharmaceuticals, understanding the financial strategies of key players is crucial. Over the past decade, Catalyst Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Amphastar's SG&A expenses grew steadily, peaking at approximately $80 million in 2023, marking a 99% increase from 2014. In contrast, Catalyst's expenses surged dramatically, especially from 2018 onwards, culminating in a staggering $134 million in 2023, a nearly 30-fold increase since 2014. This sharp rise reflects Catalyst's aggressive expansion and investment strategies. Such financial insights are pivotal for investors and stakeholders aiming to gauge the operational efficiency and strategic direction of these companies. As the pharmaceutical industry evolves, monitoring these financial metrics will be key to understanding market dynamics.
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and Amphastar Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: argenx SE vs Amphastar Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Biogen Inc. and Amphastar Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Amphastar Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Neurocrine Biosciences, Inc. vs Amphastar Pharmaceuticals, Inc.
Sarepta Therapeutics, Inc. vs Catalyst Pharmaceuticals, Inc.: SG&A Expense Trends
Apellis Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
Xenon Pharmaceuticals Inc. and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Amphastar Pharmaceuticals, Inc.
Comparing SG&A Expenses: Catalyst Pharmaceuticals, Inc. vs Galapagos NV Trends and Insights
Comparing SG&A Expenses: Catalyst Pharmaceuticals, Inc. vs Xencor, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc.